ヒトマイクロバイオーム（微生物）の世界市場：プロバイオティクス、プレバイオティクス、食品、医療食、デバイス、薬など...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKETS COVERED 14
1.3 STAKEHOLDERS 15
1.4 MARKET SCOPE 15

2 RESEARCH METHODOLOGY 17
2.1 MARKET SIZE ESTIMATION 18
2.2 MARKET CRACKDOWN & DATA TRIANGULATION 21
2.3 MARKET SHARE ESTIMATION 21
2.3.1 KEY DATA FROM SECONDARY SOURCES 21
2.3.2 KEY DATA FROM PRIMARY SOURCES 22
2.3.3 KEY INDUSTRY INSIGHTS 22
2.3.4 ASSUMPTIONS 23

3 EXECUTIVE SUMMARY 24

4 PREMIUM INSIGHTS 27
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN GLOBAL HUMAN MICROBIOME MARKET 27
4.2 HUMAN MICROBIOME MARKET SNAPSHOT 28
4.3 NORTH AMERIA WILL BE THE FASTEST GROWING MARKET IN THE FORECAST PERIOD 29
4.4 HUMAN MICROBIOME MARKET: BY DISEASES 29
4.5 HUMAN MICROBIOME MARKET: BY PRODUCT 30
4.6 LIFE CYCLE ANALYSIS, BY GEOGRAPHY 30
4.7 HUMAN MICROBIOME MARKET: BY APPLICATION 31

5 MARKET OVERVIEW 32
5.1 INTRODUCTION 33
5.1.1 HUMAN MICROBIOME MARKET, BY APPLICATION 33
5.1.2 HUMAN MICROBIOME MARKET, BY DISEASE 34
5.1.3 HUMAN MICROBIOME MARKET, BY PRODUCT 34
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Human microbiome therapy, an emerging market 36
5.2.1.2 Human microbiome represents as new validated targets for drug development 37
5.2.1.3 Need for early disease detection and diagnosis driving the use of microbiomes in molecular diagnostics 37
5.2.2 RESTRAINTS 38
5.2.2.1 Lack of proper detailed research 38
5.2.2.2 Barriers to prove causal link between dysbiosis and disease 38
5.2.3 OPPORTUNITIES 39
5.2.3.1 IND requirements for fecal microbiota may boost market growth 39
5.2.3.2 Joint ventures, collaborations, & partnerships between companies 39
5.2.4 THREATS 40
5.2.4.1 Government regulations 40
5.2.5 BURNING ISSUES 41
5.2.5.1 Abundant opportunities in the microbiome field and tremendous research investments may boost the market 41
5.2.5.2 Various microbiome therapeutic products in various stages of development 42

6 INDUSTRY TRENDS 43
6.1 INTRODUCTION 43
6.2 INDUSTRY TRENDS 43
6.3 PORTER’S FIVE FORCES ANALYSIS 44
6.3.1 THREAT FROM NEW ENTRANTS 44
6.3.2 THREAT FROM SUBSTITUTES 45
6.3.3 BARGAINING POWER OF SUPPLIERS 45
6.3.4 BARGAINING POWER OF BUYERS 45
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 46
6.4 PEST ANALYSIS 46
6.4.1 POLITICAL FACTORS 46
6.4.2 ECONOMIC FACTORS 46
6.4.3 SOCIAL FACTORS 47
6.4.4 TECHNOLOGICAL FACTORS 47
6.5 STRATEGIC BENCHMARKING 47
6.5.1 RESEARCH AND TECHNOLOGY INTEGRATION & PRODUCT DEVELOPMENT 47
6.5.2 ENTRY INTO THE CHRONIC LIFESTYLE DISEASES MARKET 48

7 HUMAN MICROBIOME MARKET, BY DISEASE 50
7.1 INTRODUCTION 51
7.2 DIABETES 53
7.3 OBESITY 54
7.4 AUTOIMMUNE DISORDERS 56
7.5 CANCER 57
7.6 ACUTE DIARRHEA 59
7.7 MENTAL DISORDERS 60
7.8 OTHER DISEASES 63
 
8 HUMAN MICROBIOME MARKET, BY APPLICATION 65
8.1 INTRODUCTION 66
8.2 THERAPEUTICS 68
8.3 DIAGNOSTICS 70

9 MARKET, BY PRODUCT 72
9.1 INTRODUCTION 73
9.2 PROBIOTICS 75
9.3 PREBIOTICS 77
9.4 FOODS 78
9.5 MEDICAL FOOD 80
9.6 OTHER PROBIOTIC SUPPLEMENTS 81
9.7 DEVICES 83
9.8 DRUGS 84

10 GEOGRAPHIC ANALYSIS 86
10.1 INTRODUCTION 87
10.2 NORTH AMERICA 88
10.3 EUROPE 90
10.4 ASIA-PACIFIC 92
10.5 REST OF THE WORLD (ROW) 95

11 COMPETITIVE LANDSCAPE 97
11.1 OVERVIEW 97
11.2 NEW PRODUCT LAUNCHES 99
11.3 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS 99
11.4 EXPANSIONS 102
11.5 CLINICAL /RESEARCH STUDIES 102
11.6 PATENT FILLINGS AND APPROVALS 103
11.7 OTHER DEVELOPMENTS 105

12 COMPANY PROFILES 107
(Overview, Financials, Products & Services, Strategy, & Developments)*
12.1 INTRODUCTION 107
12.2 ENTEROME BIOSCIENCE 108
12.3 SECOND GENOME, INC. 111
12.4 MICROBIOME THERAPEUTICS LLC. 114
12.5 VEDANTA BIOSCIENCES, INC. 117
12.6 METABIOMICS CORPORATION 119
12.7 E.I. DU PONT DE NEMOURS AND COMPANY 122
12.8 MERCK & CO., INC. 126
12.9 YAKULT HONSHA CO., LTD. 128
12.10 OSEL, INC. 131
12.11 VITHERA PHARMACEUTICALS 133
12.12 GT BIOLOGICS LTD. 136
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

13 APPENDIX 139
13.1 INSIGHTS OF INDUSTRY EXPERTS 139
13.2 DISCUSSION GUIDE 140
13.3 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE 143
13.4 AVAILABLE CUSTOMIZATIONS 144
1.1. RELATED REPORTS 145